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Background: Noncompliance is a major problem for patients with a psychotic disorder. Two 
important risk factors for noncompliance that have a severe negative impact on treatment 
outcomes are impaired illness insight and lack of motivation. Our cross-sectional study explored 
how they are related to each other and their compliance with depot medication.
Methods: Interviews were conducted in 169 outpatients with a psychotic disorder taking depot 
medication. Four patient groups were defined based on low or high illness insight and on low 
or high motivation. The associations between depot-medication compliance, motivation, and 
insight were illustrated using generalized linear models.
Results: Generalized linear model showed a significant interaction effect between motivation 
and insight. Patients with poor insight and high motivation for treatment were more compliant 
(94%) (95% confidence interval [CI]: 1.821, 3.489) with their depot medication than patients 
with poor insight and low motivation (61%) (95% CI: 0.288, 0.615). Patients with both insight 
and high motivation for treatment were less compliant (73%) (95% CI: 0.719, 1.315) than those 
with poor insight and high motivation.
Conclusion: Motivation for treatment was more strongly associated with depot-medication 
compliance than with illness insight. Being motivated to take medication, whether to get better or 
for other reasons, may be a more important factor than having illness insight in terms of improv-
ing depot-medication compliance. Possible implications for clinical practice are discussed.
Keywords: noncompliance, psychotic disorder, illness insight, motivation, depot medication, 
schizophrenia
Introduction
Nonadherence to antipsychotic medication has been shown to be a major obstacle to 
achieving successful treatment outcomes in patients with psychotic disorders.1 Approxi-
mately 60% of these patients have difficulty in being adherent over time, leading to 
problems such as inconsistent symptom control, more relapses, more hospitalizations, 
and more suicide attempts.2,3 Patient, treatment, and environment-related risk factors 
have all been associated with nonadherence.4 This article focuses on two important 
patient risk factors that appear to have a great impact on whether patients adhere to 
their prescribed medication regimen: illness insight and motivation for treatment.
Illness insight has been defined by David5 as 1) the recognition that one has a mental 
illness, 2) the recognition of the need for treatment, and 3) the ability to relabel unusual 
mental events as pathological. Of patients with a psychotic disorder, approximately 
50% to 75% have only a limited degree of illness insight, which often results in poorer 
treatment outcomes.6–8
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The relationship between insight and medication adher-
ence is somewhat ambiguous:9 while some studies showed 
a clear positive association,10–12 others either failed to find an 
association or showed that the effect of insight on medication 
adherence diminished over time.13,14 In sum, illness insight is 
not enough to improve medication compliance. Neither is it a 
prerequisite for taking medication. Perhaps patients with poor 
insight who accept their medication are simply motivated to 
take medication, whether or not they completely understand 
or acknowledge their mental illness.
Motivation has been defined as “the probability that a per-
son will enter into, continue, and adhere to a specific change 
strategy”.15 Motivation for treatment among psychotic patients 
has been studied extensively in therapeutic settings, and is 
positively associated with effective treatment outcomes.16 
Often, however, motivation for treatment is lacking in patients 
with psychotic disorders such as schizophrenia.17 As a result, 
these patients are less willing to adhere to antipsychotic medi-
cation prescriptions, to engage in treatment activities, or to 
show up for appointments. Neither are they likely to benefit 
from their treatment. As a negative symptom of schizophre-
nia disorder, lack of motivation is a common problem that is 
difficult for patients and clinicians to address.
To increase the benefits of treatment, patients can be 
prescribed antipsychotic depot medication, which is easier 
to monitor, has long-lasting effects, and reduces relapse 
rates more than oral medication.18 However, since the 
effects of depot medication in different treatment settings 
are somewhat unclear,19 we decided to focus on the effects 
of antipsychotic depot medication among outpatients with 
a psychotic disorder.
Thus, impaired insight and lack of motivation can have 
a negative impact on medication compliance. It remains 
unclear, however, how these risk factors relate to each other 
and to medication compliance. This is important for develop-
ing intervention studies that might focus more on developing 
illness insight or increasing motivation for treatment. There-
fore, in a cross-sectional study we explored the associations 
between illness insight, motivation for treatment, and adher-
ence to antipsychotic depot medication.
Methods
Patients
Baseline data were obtained from 169 patients participating 
in Money for Medication, an ongoing randomized controlled 
trial on the effectiveness of financial incentives for improv-
ing adherence to depot medication (for protocol details, see 
Noordraven et al20). Patients were recruited from three mental 
health care institutions in the Netherlands that primarily treat 
patients with psychotic and other severe mental disorders 
(often with comorbid substance-use disorder). Patients 
met the following inclusion criteria: age between 18 and 
65 years, having a psychotic disorder, taking antipsychotic 
depot medication or an indication to start using it, receiving 
outpatient treatment, and having given written informed 
consent on participating in a randomized controlled trial. 
There were two exclusion criteria: inability to participate due 
to cognitive impairments and inability to participate due to 
insufficient understanding of the Dutch language. The study 
was approved by the accredited Dutch Medical Ethical Trial 
Committee at Erasmus University Medical Center (Trial 
Registration NTR2350).
Procedure
Candidate participants were selected from the caseloads on 
the basis of the inclusion and exclusion criteria. The baseline 
interview was conducted after written informed consent 
had been given and before randomization. All interviews 
were conducted by psychologists who had received pro-
fessional training in the Positive And Negative Syndrome 
Scale (PANSS) and Health of the Nation Outcome Scales 
(HoNOS) interview and its subsequent scoring procedures. 
Per interview, all participants received a remuneration of 
€20. Demographic variables, DSM-IV diagnoses on axis I 
and II, and psychiatric history were collected during the first 
interview and from patients’ medical records. In the trial, 
randomization took place after the first interview, whereas 
for this study all patients were treated as one sample. For a 
more detailed protocol description, see Noordraven et al.20
Measurements
Medication compliance
The medication possession ratio (MPR), first reported by 
Sclar et al21 was used as a measure for depot-medication com-
pliance. MPR is defined as the number of accepted depots of 
antipsychotic medication divided by the number of depots of 
antipsychotic medication prescribed, that is, the number 
of supplies needed for continuous use of antipsychotic 
medication. Each patient’s MPR at baseline was determined 
on the basis of the 4 months prior to the baseline interview.
illness insight
Insight was measured using the Dutch version of the 
PANSS,22 a 30-item semistructured interview intended to 
determine the presence of positive and negative symptoms 
and general psychopathology. Illness insight was assessed on 
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the basis of item A12 of the PANSS “Do you have a psychi-
atric disorder or mental health problem?” in which the patient 
is also asked to elaborate his answer. Specifically, this item 
describes a patient’s ability to acknowledge his or her psychi-
atric disorder, need for treatment, and ability to make future 
plans. Items were scored on a scale from 1 (illness insight 
present) to 7 (active denial of having a psychiatric disorder). 
Response scores for insight (item A12) were dichotomized 
into patients having “poor insight” (scoring 3–7 on the insight 
item) and “high illness insight” (scoring 1–2).
Motivation for treatment
Motivation for treatment was assessed on the basis of an item 
added to the Dutch version of the HoNOS,23 which describes 
a patient’s motivation in terms of cooperation, personal 
interest, and possible resistance to treatment: “How moti-
vated are you for your current treatment?” As with the other 
items of the HoNOS, this item was rated on a 5-point scale 
ranging from 0 (no problems) to 4 (very severe problems). 
Patient scores were dichotomized into “high motivation for 
treatment” (scoring 0–1 on the motivation item) and “low 
motivation for treatment” (scoring 2–4).
Missing values
Due to administrative errors, data for the total sample lacked 
baseline data for three patients. Similarly, 13 values were 
missing for compliance rates, 2 for motivation, and 2 for 
insight. One patient had missing values for both motivation 
and insight. Therefore, in total, 19 patients were excluded 
from the analyses. Sensitivity analyses using imputed data 
on average values did not show different results.
statistical analyses
We used generalized linear models to estimate the effect of 
motivation and insight on the number of depots accepted as 
a percentage of the number of depots prescribed. Because 
MPR values are proportion data, we assumed binomial error 
distribution and used the logit link function. Patients were 
grouped into four categories: 1) those with low motivation 
and poor insight (n=62); 2) those with high motivation but 
poor insight (n=17); 3) those with low motivation but a high 
degree of insight (n=17); and 4) those whose motivation and 
illness insight were high (n=54). All groups were entered as 
one categorical predictor variable. Since patients with low 
motivation and poor insight had the lowest compliance rate 
(65.8%), we used this category as our reference group. All 
statistical analyses were performed using SPSS version 21.0 
(IBM Corporation, Armonk, NY, USA).
Results
Patient characteristics
Table 1 presents the sociodemographic and clinical data 
of all patients at baseline. Data for motivation, insight, 
and medication compliance at baseline are presented in 
Table 2.
relationship between insight and 
compliance
Insight was positively associated with MPR (β=1.471, 
95% confidence interval [CI]: [0.468, 1.00], P,0.001), 
(Table 2). Patients with high illness insight were almost 10% 
Table 1 Baseline characteristics of the study sample (N=166)
Variable Descriptive 
statistics
age (years), mean (sD) 40.7 (10.2)
sex, N (%)
Male
Female
124 (74.3)
42 (25.1)
Duration of illness (years), mean (sD) 12.3 (8.5)
ethnicity, N (%)
Dutch
surinamese
Other
64 (38.3)
39 (23.4)
63 (38.3)
Outpatient commitment measures, N (%)* 60 (36.7)
Diagnosis, N (%)
schizophrenia paranoid type
schizoaffective disorder
Psychotic disorder NOs
schizophrenia disorganized type
Other schizophrenic disorders
96 (57.5)
18 (10.8)
18 (10.8)
11 (6.6)
24 (14.3)
Medication at baseline, N (%)
First-generation antipsychotics
second-generation antipsychotics
Depot medication
125 (75.8)
39 (23.6)
140 (82.6)
Motivation, median (interquartile range)
illness insight, median (interquartile range)
No of psych admissions,** median (interquartile range)
No of admission days,** median (interquartile range)
2 (0–2)
3 (1–4)
1 (0–3)
44 (0–120)
Notes: *Mental health law for compulsory admissions and outpatient commitment 
in the Netherlands. **Three years preceding the baseline interview.
Abbreviations: SD, standard deviation; NOS, not otherwise specified.
Table 2 Mean medication possession ratio scores at baseline 
interview by motivation and insight
Variable Medication  
possession ratio (%)
N
insight
Poor 71.9 79
high 81.6 71
Motivation
low 68.0 79
high 85.8 71
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more compliant with their prescribed antipsychotic depot 
medication than patients with poor insight.
relationship between motivation and 
compliance
Motivation, too, was positively associated with MPR 
(β=1.133, 95% CI: [0.854, 1.413], P,0.001), (Table 2). 
Patients with a high motivation for treatment were 18% more 
compliant with the antipsychotic depot medication prescribed 
to them than patients with low motivation for treatment.
insight, motivation, and their association 
with compliance
Our results showed a significant interaction effect between 
motivation and insight (Figure 1). Patients with poor insight 
but high motivation for treatment were more compliant with 
their medication (94%; β=2.655, 95% CI: [1.821, 3.489], 
P,0.001) than patients with poor insight and low motivation 
(61%; β=1.570, 95% CI: [0.288, 0.615], P,0.001). Patients 
with high insight and motivation (73%; β=1.017, 95% CI: 
[0.719, 1.315], P,0.001) and patients with high insight but 
low motivation (74%, β=1.028, 95% CI: [0.547, 1.510], 
P,0.001) were more compliant than patients with low 
motivation and poor insight (61%). Switching our reference 
category to patients with high motivation and insight (73%) 
allowed us to compare their medication compliance with 
patients with high insight and low motivation (74%), which 
showed no significant difference. However, patients with 
high motivation and poor insight (94%) were more compli-
ant than those with high insight. This suggests that insight 
is not only less strongly associated with compliance than 
motivation, but also that the level of compliance in patients 
with high motivation may be reduced by insight.
Discussion
The main finding of our study was that motivation for 
treatment seems to be more important than illness insight 
for compliance with depot medication in psychotic dis-
order patients. Specifically, we found that patients with a 
high motivation for treatment were most compliant with 
their medication, independent of insight. Unexpectedly, 
patients with high insight and high motivation showed less 
compliance as compared to patients with poor insight and 
high motivation.
It may seem contradictory that patients with poor illness 
insight were willing to accept their antipsychotic depot 
medication. From this perspective, one could argue that 
having illness insight is not a prerequisite for achieving 
compliance. In other words, it may be more important to be 
motivated to take medication – whether to get better, or for 
other reasons – than to have illness insight with regard to 
improving depot-medication compliance.
Our findings may have two important clinical conse-
quences for increasing compliance with depot medication. 
First, we found that patients with poor insight who were 
highly motivated for treatment had over 30% more com-
pliance. Therefore, it may be more important in patients 
with poor insight to improve motivation for treatment as a 
first step, for example, by using motivational interviewing 
strategies24, instead of immediately trying to enhance illness 
insight.
Second, when addressing illness insight, we have to be 
aware of possible negative consequences regarding compli-
ance, since we found that a high degree of illness insight 
in highly motivated patients was accompanied by a level 
of compliance that was ~20% lower than that in patients 
with poor insight. This suggests that greater illness insight 
is not necessarily associated with higher compliance rates 
in patients who are highly motivated, but may sometimes 
be accompanied by lower medication acceptance. This is 
surprising, since it has always been assumed that it would be 
better to have good insight. Although our finding that greater 
illness insight does not lead to better compliance is counterin-
tuitive, it may be that patients who are highly motivated and 
also have illness insight want to use other treatment options, 
such as oral medication and/or psychotherapy.
Limitations
Three important limitations of this study should be consid-
ered. First, our cross-sectional design makes it difficult to 
infer causality.25 Longitudinal and experimental studies are Figure 1 interaction effect between patient categories.
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needed to further study the associations between motivation, 
illness insight, and compliance.
The second limitation is that motivation and insight 
were both measured using a single item. In previous studies, 
however, the PANSS insight item showed high correlations 
with questionnaires assessing insight such as the Insight 
and Treatment Attitudes Questionnaire or the Schedule 
for the Assessment of Insight.26,27 With respect to the 
HoNOS motivation item, earlier studies also found high and 
significant correlations with scales measuring the motivation 
construct, including the Treatment Entry Questionnaire and 
the Treatment Motivation Scale.28
The third limitation is that only patients on depot medica-
tion participated in this study. Associations between illness 
insight and motivation may be different for patients on daily 
oral medication.
Conclusion
Motivation and illness insight both play an important role 
in a patient’s acceptance of antipsychotic depots. Attempts 
to improve compliance should be made carefully, first by 
assessing their level of motivation and illness insight. The 
clinician can then make an informed decision on the extent 
of any interventions intended to improve compliance through 
improved motivation and/or insight. Our results suggest 
that it may be more important to improve compliance by 
improving motivation than by enhancing insight, especially 
in patients whose insight is already poor. It will be interesting 
to investigate whether this is also the case with compliance 
with daily oral antipsychotic medications. Ultimately, dif-
ferent treatment protocols might be used for patients with 
different combinations of insight and motivation. In every-
day practice, it may be best for clinicians not to focus on 
either insight or motivation, but to recognize that the most 
important factor in understanding compliance with antipsy-
chotic medication lies in the combination of the two. Future 
research should establish whether these associations are valid 
over time and which interventions clinicians should use to 
improve motivation and illness insight among patients with 
a psychotic disorder.
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